FOL-100

FOL-100 is a topically administered small molecule drug developed by Follicle Pharma for the treatment of androgenetic alopecia (male pattern hair loss). It is formulated as a lotion and utilizes a proprietary targeted delivery system designed to deliver active pharmaceutical ingredients directly to the hair follicle while minimizing systemic absorption. The mechanism of action for FOL-100 has not been publicly defined. As of March 2025, it is in Phase 1 clinical trials in Israel, where its safety, tolerability, and usability are being compared with oral finasteride. The product aims to address limitations and side effects associated with oral therapies by providing localized treatment for hair loss[1][2][3][4][5].